12 new medicines recommended for approval

EMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its February 2026 meeting.

The committee recommended granting a marketing authorisation for mCombriax (influenza and COVID-19 mRNA vaccine), the first combined messenger RNA vaccine for protecting people aged 50 years and older against COVID-19 and seasonal influenza (flu). According to data released by the World Health Organization (WHO), as of 1 February 2026, there had been 281,728,062 cases of COVID-19 reported in Europe. Seasonal influenza also presents a significant burden, with up to 50 million symptomatic cases of seasonal influenza occurring every year in the European Economic Area (EEA). See more details in the news announcement in the grid below.

The CHMP recommended granting a conditional marketing authorisation for Ojemda (tovorafenib), to treat patients aged six months and older with paediatric low-grade glioma, a type of non-cancerous brain…